ERBB2 and breast cancer: Consistent with previous reports [17, 23], we found that for pre-treatment percutaneous needle biopsy samples, TN breast cancer tumors and HER2+ tumors had higher take rates than luminal tumors [16, 23, 38] (Table 1).